



Civica Insulin Initiative

Affordability and Accessibility for All Americans

Insulin is prescribed for approximately 8 million people in the United States who need it to stay alive. But the medication has not gone down in price, as usually happens when the patent expires, but up—threefold. JDRF believes that no one with diabetes should have to choose between food and shelter or insulin because of its cost. With support from JDRF and other leading healthcare organizations, Civica will manufacture and distribute biosimilar insulins, significantly lowering the cost for millions of Americans and—most importantly—save lives.

How it Works

Currently, insulin can cost between \$175 and \$300 a vial and up to \$1,000 a month. Given the urgent need to reduce the price of insulin, JDRF and other like-minded organizations have partnered with Civica, a nonprofit generic pharmaceutical company, to make insulin affordable and accessible to everyone, regardless of insurance status.

“The inability to afford insulin was even more daunting than being diagnosed with type 1 diabetes. When you’re diagnosed, you’re told that if you take care of yourself, you can live a relatively normal life, but nobody ever prepares you for not being able to afford the medication that keeps you alive. When your only option is to ration your insulin, it’s an incredibly isolating and scary place to be, and one that nobody should ever have to live through, regardless of whether they have insurance or not.”

— Grace B., 31 years old, diagnosed at age 11

Project Goals



Manufacture biosimilars for three of the most-prescribed insulins—glargine (Lantus®), lispro (Humalog®), and aspart (Novolog®)



Distribute these life-saving drugs to pharmacies and hospitals at no more than \$30/vial or \$55/box of five pen cartridges, regardless of insurance



Drive positive change for communities vastly affected by healthcare disparities, insulin affordability, and insulin accessibility



JDRF exists so type 1 diabetes (T1D) won’t. Our mission is to improve lives today and tomorrow by accelerating life-changing breakthroughs to cure, prevent, and treat T1D and its complications through research, advocacy, and community engagement. To read more, visit jdrf.org.

Civica Insulin Initiative by the Numbers

Nearly 1/4 of people with diabetes ration or skip taking their insulin because of cost

Up to a **90 percent decrease in insulin cost** compared to market prices right now

10+ partners who have committed support for the Civica project

FAQs

What type of insulins will be produced and when?

Civica will produce three biosimilar insulins—glargine (Lantus®), lispro (Humalog®), and aspart (Novolog®). It is expected that they will be available, both in vials and in cartridges, in 2024.

How much will the insulin cost?

Civica anticipates a price of no more than \$30 per vial and \$55/box of five pen cartridges—a significant discount to prices charged to individuals today.

How will this affect people who need it the most?

There has been some progress in recent years—in select states and through certain commercial insurance providers—to lower or cap the cost of insulin. Unfortunately, these are not enough. By entirely changing the production and pricing model, Civica will be able to provide more affordable insulin options to those who are uninsured or underinsured, who may have to choose between food and rent and life-saving medicine.

What is a biosimilar?

Biosimilars are biologic drugs that are highly similar to the original drug product, which can be manufactured once the original drug patent expires.

What should people who struggle to pay for insulin do now?

JDRF has compiled a list of resources to help navigate the costs of insulin and other diabetes care supplies. Visit jdrf.org/prescription-costs to find out more.

What else has JDRF done to make insulin more affordable?

JDRF has been fighting for affordable insulin for years. We have rallied our community to call for insulin makers, health plans, employers, and the government to lower the cost of this life-saving drug. JDRF executives have met repeatedly with the leadership of each of the three major insulin manufacturers and called on them to find new ways to lower the price. To find out more, please visit jdrf.org/insulin-affordability.

Additional partners collaborating with **CIVICA** include:

Arnold Ventures

Beyond Type 1

Blue Cross Blue Shield Association
and 12 member companies

Gary and Mary West Foundation

Glen E. Tullman Fund

Intermountain Healthcare

Kaiser Permanente

Peterson Center on Healthcare

Providence

The Leona M. and Harry B. Helmsley
Charitable Trust

Transcarent

Trinity Health

Every gift takes us one step closer to curing T1D. Find out how you can support JDRF and make a difference in the lives of people with T1D by visiting jdrf.org/donate.

You can also follow us on:

 facebook.com/myjdrf

 [@JDRF/@JDRFResearch](https://twitter.com/JDRF)

 [@JDRFHQ](https://www.instagram.com/JDRFHQ)

 youtube.com/user/jdrfonline